Taspiance is a prescription drug that contains Peginterferon alfa-2a as an active ingredient. It is an antiviral medication used to treat chronic hepatitis B and C viral infections.
The active ingredient in Taspiance is Peginterferon alfa-2a, a synthetic protein that stimulates the immune system to fight viral infections.
Taspiance is primarily used to treat chronic Hepatitis B and C viral infections. It is also used in combination with other medications such as ribavirin to treat some forms of leukemia and certain types of skin cancer.
Usage and dosage:
Taspiance is an injection given under the skin. The dosage and duration of treatment will depend on the patient’s medical condition, age, weight, and response to the treatment. It is usually given once a week, and the maximum dosage is 180mcg/week.
Taspiance should be stored in a refrigerator at 2-8°C and protected from light. Do not freeze the medicine, and keep it out of the reach of children.
Mechanism of action:
Peginterferon alfa-2a works by stimulating the immune system to fight viral infections. It causes the infected cells to produce antiviral proteins that inhibit viral replication, thus reducing the viral load in the body.
Taspiance is contraindicated in patients who are allergic to Peginterferon alfa-2a, have autoimmune disorders, severe depression, or a history of suicidal thoughts. It should not be given to pregnant women or patients with decompensated liver disease.
Taspiance may interact with other medications like zidovudine, ritonavir, and other antiretroviral drugs. It should not be used in combination with other medications without medical supervision.
Common side effects of Taspiance include flu-like symptoms, headache, fatigue, loss of appetite, nausea, and vomiting. Serious side effects may include depression, suicidal thoughts, and bone marrow suppression.